BioXcellerator
BioXcellerator is a privately held regenerative medicine company delivering proprietary Wharton's jelly mesenchymal stem cell and exosome therapies at its Medellín, Colombia clinic, serving U.S. and international patients with orthopedic, autoimmune, neurological, and chronic inflammatory conditions through a direct-to-consumer medical tourism model.
- Company typePrivate
- Founded2018
- HeadquartersPhoenix, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What BioXcellerator does
BioXcellerator is a privately held regenerative medicine company that delivers stem cell therapy to patients with orthopedic and sports injuries, autoimmune and degenerative diseases, neurological conditions, chronic inflammatory disorders, and select aesthetic indications. The company is incorporated in Arizona (corporate office in Scottsdale/Phoenix) and operates its primary treatment clinic in Medellín, Colombia, where all clinical procedures are performed; treatments are not available in the United States because the company's advanced cell expansion protocols fall outside current FDA approval pathways. The company is led by CEO Eric Stoffers, CMO Dr. Karolynn Halpert, CSO Matthew Marks, and VP of Sales Jarett Smith, with a total headcount of 11–50.
The company's core technology platform is built around proprietary "BioXcellerator Signature Cells" — mesenchymal stem cells (MSCs) derived from Wharton's jelly umbilical cord tissue, cultured under hypoxic and normoxic conditions to enhance anti-inflammatory and regenerative potency, supplemented by the EVOKE exosome product line. All processing occurs at an on-site ISO-, cGMP-, and FACT-JACIE-aligned laboratory in Medellín. The company operates a wholly owned research subsidiary, BioXscience, that conducts meta-analyses, systematic reviews, and protocol-development work, and the scientific team has published in journals including ISCT Cytotherapy and Frontiers.
BioXcellerator generates revenue through direct-to-consumer medical tourism: patients pay out-of-pocket (no insurance coverage) for customized treatment plans, with a concierge team managing consultation, eligibility screening, travel, accommodations, airport transfers, and follow-up monitoring up to two years post-treatment. Pricing is not publicly disclosed; treatment is positioned as a high-end cash-pay offering for affluent U.S. and international patients, including professional athletes and celebrities, and financing options are available. The company markets primarily through content (blog, social media), patient testimonials, conference participation, and a free consultation funnel. The company has reported thousands of successful patient outcomes and a 97% patient satisfaction rate since initiating treatments in 2018.
BioXcellerator firmographics
Firmographics- Name
- BioXcellerator
- Legal name
- BioXcellerator Inc.
- Website
- https://bioxcellerator.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioXcellerator is a privately held regenerative medicine company delivering proprietary Wharton's jelly mesenchymal stem cell and exosome therapies at its Medellín, Colombia clinic, serving U.S. and international patients with orthopedic, autoimmune, neurological, and chronic inflammatory conditions through a direct-to-consumer medical tourism model.
- Ownership category
- akta.pro rank
BioXcellerator industry classification
Industry- Product category
- Regenerative Medicine Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Blood and Organ Banks (621991), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL), Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA)
Keywords
Where BioXcellerator is headquartered
LocationHeadquarters
- HQ city
- Phoenix
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BioXcellerator business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Medical Treatment Services: Direct patient payments for stem cell therapy treatments at the Medellín, Colombia clinic. Services include personalized treatment plans, concierge coordination (travel, accommodations, transfers), and ongoing follow-up care. Treatment costs are not publicly disclosed and vary based on condition and protocol complexity. Financing options are available for patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Customized treatment plans based on individual patient conditions |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
BioXcellerator product offering
Product offeringCore offering
BioXcellerator provides adult stem-cell therapy and regenerative-medicine treatment protocols using its proprietary BioXcellerator Signature Cells, mesenchymal stem cells derived from Wharton's Jelly umbilical cord tissue. Treatments are delivered via intravenous, intrathecal, intra-articular and site-specific injections at its Medellín, Colombia clinic, with adjunctive EVOKE exosome therapy and an on-site cGMP/ISO-certified laboratory and cell bank. The company additionally advances R&D through its research arm BioXscience.
Product overview
BioXcellerator is a stem cell therapy and regenerative medicine company offering a portfolio of treatment protocols built on its proprietary Signature Cells technology platform. The core offering consists of high-potency mesenchymal stem cells (MSCs) derived from Wharton's Jelly umbilical cord tissue, available in both hypoxic and normoxic variants, supplemented with MSC exosomes. These are delivered through a suite of named treatment protocols addressing specific conditions including: Fountain of Youth Protocol for Women, Health Optimization and Sports Recovery, Diabetes Treatment, Orthopedic and Sports Injuries, Spine and Disc Conditions, Autoimmune Diseases, Cosmetic and Skin Rejuvenation, Osteoarthritis, Rheumatoid Arthritis, Crohn's Disease and Ulcerative Colitis, Multiple Sclerosis, Sexual Wellness and Erectile Dysfunction, Chronic Pain, Neurological Conditions, Spinal Cord Injuries, and Autism Spectrum Disorder. All treatments are administered at the company's clinic in Medellín, Colombia, with treatments customized per patient based on individual health needs.
Differentiator
Problem solved
Functional benefit
Brands
- BioXscience: A subsidiary of BioXcellerator responsible for planning and executing research and innovation activities, including meta-analyses, systematic reviews, and the development of best-practice, patient-specific protocols for regenerative medicine.
- BioXcellerator Signature Cells
- EVOKE Exosomes (Extracellular Vesicles Optimizing Key Enhancements)
- Fountain of Youth Protocol for Women
- Health Optimization and Sports Recovery
Products and services
- BioXcellerator Signature Cells (Wharton's Jelly MSC therapy)
- Health Optimization and Sports Recovery Protocol
- Fountain of Youth Protocol for Women
- Diabetes Stem Cell Treatment
- Orthopedic and Sports Injuries Treatment
- Spine and Disc Conditions Treatment
- Autoimmune Diseases Treatment
- Cosmetic and Skin Rejuvenation Treatment
- Osteoarthritis Stem Cell Treatment
- Rheumatoid Arthritis Stem Cell Treatment
- Crohn's Disease and Ulcerative Colitis Treatment
- Multiple Sclerosis Stem Cell Treatment
- Sexual Wellness and Erectile Dysfunction Treatment
- Chronic Pain Stem Cell Treatment
- Neurological Conditions Treatment
- Spinal Cord Injuries Stem Cell Treatment
- Autism Spectrum Disorder Treatment
- EVOKE Exosome Therapy
- BioXscience Research Services
Quantifiable outcome
- 97% patient satisfaction after post-treatment survey
- +1 more outcomes
Companies that use BioXcellerator
Customer profileNamed customers10 records
Segments7 records
Ideal customer profiles1 record
BioXcellerator technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BioXcellerator partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
BioXcellerator competitors and assessment
Company assessmentDirect peers
- Regenexx: Regenexx is the largest U.S. orthopedic stem cell and platelet-rich plasma (PRP) network, specializing in autologous MSC/BMC injections for joints, spine, and sports injuries. It directly overlaps BioXcellerator's core orthopedic and sports injury segment but operates within FDA-permitted autologous-only constraints rather than allogeneic Wharton's Jelly MSC.
- Celltex Therapeutics: Celltex operates a Houston-based stem cell bank and a Mexico-based clinic offering autologous MSC therapies to U.S. patients via medical tourism, similar to BioXcellerator's Colombia model. It is a comparable allogeneic MSC + medical tourism peer targeting orthopedic, autoimmune, and degenerative indications.
- DVC Stem: DVC Stem provides adult stem cell therapy via a Grand Cayman clinic, using umbilical cord-derived MSCs for orthopedic, autoimmune, and degenerative conditions - highly overlapping protocol, donor-source, and medical-tourism go-to-market as BioXcellerator.
- Swiss Medica: Swiss Medica runs stem cell clinics in Switzerland, Serbia, and Russia treating orthopedic, neurological, and autoimmune conditions with MSC-based therapies. Multi-site international medical-tourism stem cell clinic directly comparable to BioXcellerator in indication breadth and patient model.
- Okyanos Heart Institute: Okyanos is a Bahamas-based regenerative medicine clinic offering adult stem cell therapy for cardiac, orthopedic, and degenerative conditions under a medical-tourism model. Closely overlaps BioXcellerator's indication portfolio and international patient concierge model.
- StemGenex: StemGenex is a U.S.-based stem cell treatment provider marketing adipose- and bone-marrow-derived therapies for a broad indication set. Direct overlap in indications (MS, autoimmune, orthopedic) and direct-to-consumer marketing approach; comparable allogeneic-adjacent treatment model.
- Panama Stem Cell Center: Panama Stem Cell Center treats U.S. and international patients at a Panama City clinic with MSC-based therapies for orthopedic, autoimmune, and degenerative conditions. Closely overlapping Latin America medical-tourism stem cell clinic peer with similar protocols and pricing posture.
Emerging players
- Global Stem Cells: Global Stem Cells is a stem cell treatment group running clinics and educational/advisory programs targeting patients with degenerative diseases across multiple countries. Less brand-saturated than BioXcellerator but overlapping indication breadth and medical-tourism positioning.
- CelluGen Biotech: CelluGen offers exosome-based regenerative therapies alongside stem cell products, adjacent to BioXcellerator's EVOKE exosome line and Signature Cells. Overlaps as an emerging exosome/MSC competitor with direct-to-patient marketing.
Others
- Innovative Medicine: Innovative Medicine operates as a regenerative-medicine clinic aggregator and concierge referral service that routes U.S. patients to international stem cell providers. Comparable distribution role to the medical-tourism concierge channel BioXcellerator uses, but competes for the same inbound patients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BioXcellerator social profiles
Digital presenceBioXcellerator financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioXcellerator leadership team
Management profileNumber of profiles
Profiles7 records
BioXcellerator subsidiaries and ownership
Company hierarchySubsidiaries1 record
BioXcellerator funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioXcellerator M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioXcellerator
What does BioXcellerator do?
BioXcellerator provides adult stem-cell therapy and regenerative-medicine treatment protocols using its proprietary BioXcellerator Signature Cells, mesenchymal stem cells derived from Wharton's Jelly umbilical cord tissue. Treatments are delivered via intravenous, intrathecal, intra-articular and site-specific injections at its Medellín, Colombia clinic, with adjunctive EVOKE exosome therapy and an on-site cGMP/ISO-certified laboratory and cell bank. The company additionally advances R&D through its research arm BioXscience.
Is BioXcellerator a public or private company?
BioXcellerator is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioXcellerator founded?
BioXcellerator was founded in 2018. It employs 11 to 50 people.
Where is BioXcellerator based?
BioXcellerator is headquartered in Phoenix, United States, in the North America region.
How does BioXcellerator make money?
One revenue line is on record: medical Treatment Services.
Who are BioXcellerator's main competitors?
Direct peers on record are Regenexx, Celltex Therapeutics, DVC Stem, Swiss Medica, Okyanos Heart Institute, StemGenex and Panama Stem Cell Center. Emerging players are Global Stem Cells and CelluGen Biotech. Innovative Medicine is listed as an others.
Does BioXcellerator have an API?
No public API is recorded for BioXcellerator.
What industry is BioXcellerator in?
BioXcellerator's product category is Regenerative Medicine Services. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 325414 and its SIC code is 2836.